Due to a production error, the Acknowledgements section was not included in the article. The acknowledgements section should read:
“ The authors thank Nanjing Jiangbei New Area Biopharmaceutical Public Service Platform for the quantification of Short-Chain Fatty Acids. Many thanks to Pro. Lu, our academic and life mentor, for strong spiritual support.”
The original version of this article has been updated.
Summary
Keywords
methotrexate, magnesium isoglycyrrhizinate, gut-liver axis, bacterial translocation, gut microbiota
Citation
Frontiers Production Office (2022) Erratum: Modulation of Gut Microbiota by Magnesium Isoglycyrrhizinate Mediates Enhancement of Intestinal Barrier Function and Amelioration of Methotrexate-Induced Liver Injury. Front. Immunol. 13:976502. doi: 10.3389/fimmu.2022.976502
Received
23 June 2022
Accepted
23 June 2022
Published
04 July 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: production.office@frontiersin.org
This article was submitted to Mucosal Immunity, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.